Last week, we discussed how the large incentives for pharmaceutical executives to meet short term financial targets (that is, "making their numbers") may be an important cause of their firms' decreasing capacity to fulfill their most basic mission, manufacturing pure, unadulterated medicines.
In the news recently were two examples of how other health care leaders are incentivized to meet short-term financial targets.
University of California